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https://doi.org/10.1186/s40644-019-0279-4RESEARCH ARTICLE Open AccessBreast MRI and tumour biology predict
axillary lymph node response to
neoadjuvant chemotherapy for breast
cancer
Samia Al-Hattali1, Sarah J. Vinnicombe2,3, Nazleen Muhammad Gowdh4, Andrew Evans4, Sharon Armstrong5,
Douglas Adamson5, Colin A. Purdie6 and E. Jane Macaskill1*Abstract
Background: In patients who have had axillary nodal metastasis diagnosed prior to neoadjuvant chemotherapy for
breast cancer, there is little consensus on how to manage the axilla subsequently. The aim of this study was to
explore whether a combination of breast magnetic resonance imaging (MRI) assessed response and primary
tumour pathology factors could identify a subset of patients that might be spared axillary node clearance.
Methods: A retrospective data analysis was performed of patients with core biopsy-proven axillary nodal metastasis
prior to commencement of neoadjuvant chemotherapy (NAC) who had subsequent axillary node clearance (ANC)
at definitive breast surgery. Breast tumour and axillary response at MRI before, during and on completion of NAC,
core biopsy tumour grade, tumour type and immunophenotype were correlated with pathological response in the
breast and the number of metastatic nodes in the ANC specimens.
Results: Of 87 consecutive patients with MRI at baseline, interim and after neoadjuvant chemotherapy who underwent
ANC at time of breast surgery, 33 (38%) had no residual macrometastatic axillary disease, 28 (32%) had 1–2 metastatic
nodes and 26 (30%) had more than 2 metastatic nodes. Factors that predicted axillary nodal complete response were MRI
complete response in the breast (p < 0.0001), HER2 positivity (p = 0.02) and non-lobular tumour type (p = 0.015).
Conclusion: MRI assessment of breast tumour response to NAC and core biopsy factors are predictive of response in
axillary nodes, and can be used to guide decision making regarding appropriate axillary surgery.
Keywords: Neoadjuvant chemotherapy, Axilla lymph node, Breast cancer, Magnetic resonance imaging, Sentinel node
biopsyIntroduction
In the past two decades, sentinel node biopsy (SNB) has
become standard practice for surgically staging the axilla
in patients having primary surgery for clinically node-
negative breast cancers, replacing the more morbid
procedure of axillary node clearance (ANC). With in-
creasing use of neoadjuvant chemotherapy (NAC) to
downsize breast tumours to achieve breast conservation,
there is little consensus on how to manage the axilla,© The Author(s). 2019 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/ze
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Full list of author information is available at the end of the articlewith varying practices including SNB before or after
chemotherapy and ANC [1]. In many units, ANC has
remained the definitive axillary procedure after NAC if
pre-treatment axillary ultrasound (AUS) and core biopsy
confirmed nodal positivity. However, NAC has been
demonstrated to eradicate nodal metastasis in up to 40%
of patients with human epidermal growth factor receptor
2 (HER2) negative tumours, and up to 75% of HER2
positive patients treated with trastuzumab [2–5].
The feasibility and accuracy of SNB post-NAC in clin-
ically node-negative patients has been established, with
false-negative rates (FNR) of 8–11% [6–12]. A recent
meta-analysis of the accuracy and reliability of sentinelle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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biopsy-proven node-positive breast cancer demonstrated
a false-negative rate with use of dual techniques of 11%
compared with 19% with single mapping [13]. It also
confirmed findings from previous studies showing that a
higher number of nodes removed improved accuracy
(FNR 20% when one node was removed, 12% with two
nodes removed and 4% with removal of three or more
nodes) [14–17].
It is known that the response within axillary nodal me-
tastases correlates with that seen in the breast tumour
[14, 18]. However, it would be advantageous to deter-
mine pre-operatively which patients have had a suffi-
ciently good response to NAC in the axilla to allow
potential downstaging of axillary surgery and avoidance
of the morbidity of an unnecessary ANC.
The accuracy of MRI in predicting the presence of re-
sidual breast disease after NAC has been demonstrated
in several studies and systematic reviews [19–21], with
high negative predictive values (NPV) for pathological
Complete Response (pCR), particularly in HER2 positive
and triple negative disease [22]. What is not clear is the
extent to which MRI reflects residual axillary nodal
disease and response in the axilla in the context of neo-
adjuvant chemotherapy. Indeed, a systematic review of
non-invasive nodal restaging in node-positive patients
after NAC from 2015 found extreme heterogeneity pre-
cluding pooled analysis, and highly variable reported
positive predictive values for axillary pathological complete
response. It concluded that there were no accurate non-
invasive restaging techniques [23]. Thus, this remains an
area of unmet clinical need.
The aim of this study was to attempt to identify a sub-
set of patients defined by MRI assessed response and
primary tumour pathology factors who might be spared
ANC.
Methods
This was a retrospective audit of data from a consecutive
series of patients with a pathological diagnosis of breast
cancer and proven nodal metastasis who received NAC
within a single centre between September 2010 to June
2015. Only patients who had undergone ultrasound-guided
core biopsy of ultrasonographically abnormal nodes (cor-
tical thickness > 2.3mm) with proven axillary node metasta-
sis prior to starting chemotherapy were included. After
completion of NAC, all patients underwent axillary node
clearance (ANC) as per the standard local policy, regardless
of the response. Local ethical approval was obtained for
collection, analysis and presentation of data.
Patients were scheduled for breast MRI to assess the
primary tumour and axilla before (pre-treatment), after
3 cycles (interim) and at the end of (post) chemotherapy.
T2 weighted sequences and standard semi-dynamiccontrast-enhanced MRI was performed with a fat-
suppressed T1 weighted spoiled gradient echo sequence,
time 45–50 s per acquisition, repeated out to 8 min.
Final MRI response was assessed according to modified
Response Evaluation Criteria in Solid Tumours (RECIST)
1.1, and categorised as complete response (MRI CR), partial
response (MRI PR), stable disease (MRI SD), or progressive
disease (MRI PD) [24], based on the presence and size of
enhancing masses and non-mass enhancement. No en-
hancement in the tumour bed or in a residual mass, or no
enhancement above background parenchymal enhance-
ment at any phase of contrast-enhanced imaging, were
denoted MRI CR; an MRI PR occurred when a residual
mass or area of non-mass enhancement had reduced by
more than 30% in maximum diameter. MRI results were
derived from the clinical report, with review of axillary find-
ings on MRI re-reported by an experienced breast radiolo-
gist (SJV) blinded to the pathological outcome.
Axillary nodes were assessed on MRI as normal, ab-
normal or borderline on each of the three MRI scans ac-
cording to nodal morphology and size on T2 weighted
and contrast enhanced T1 weighted sequences. Normal
lymph nodes were those with uniform cortical thick-
nesses no more than 2.5 mm. Borderline nodes were
those with mild cortical thickening more than 2.5 mm,
either uniform or eccentric, and abnormal nodes were
those with clearly abnormal size and morphology. At
ultrasound, cortical thickness more than 2.3 mm was de-
scribed as abnormal. Where ultrasound nodal response
had not been recorded, available images were reviewed
and assessed retrospectively by a radiologist (NMG)
blinded to the MRI response to treatment.
Pathological response in the primary breast tumour
was classified as: [25]
1. Pathologic complete Response (pCR), no residual
invasive disease present;
2. Near complete Response, the residual invasive
disease has a percentage reduction in cellularity of
> = 90%;
3. Partial Response, reduction in cellularity of > 50%
and < 90%;
4. Minimal Response, reduction in cellularity 1–50%;
5. No pathological response, 0% reduction in cellularity.
Axillary lymph nodes were considered negative on path-
ology if no macrometastasis (foci > 2.0 mm) was identified
on standard haematoxylin and eosin staining. The pres-
ence of scarring, micrometastasis (Mic) (foci 0.2–2.0 mm)
or isolated tumour cells (ITC) (foci < 0.2 mm or < 200 can-
cer cells in one section) was recorded and analysed.
The response of the breast tumour on MRI, and of the
axillary nodes on MRI and ultrasound, together with core
biopsy tumour grade, tumour type and immunophenotype
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breast and the number of abnormal nodes in the nodal
clearance specimens.
The data were plotted in contingency tables and the
significance tests used were Chi squared, Fisher exact,
and Pearson correlation using vassarstats.com. Sensitiv-
ity, specificity and univariate analysis was performed
using SPSS v 22.0.
Results
Of 176 patients treated with NAC during the study
period, 117 patients had core biopsy-confirmed axillary
nodal metastasis prior to treatment. Eighty-seven pa-
tients had available MRI data for analysis from before,
during and after NAC and thus formed the study cohort.
This number included two patients who were planned to
receive 4 cycles only of NAC, and had MRI before and
after 4 cycles (called interim for analysis purposes), and
4 patients who received 6 cycles and had only pre-and
post treatment MRI scans.
The median age was 50 years (range 24–79). Baseline
characteristics are shown in Table 1. In eight patients,
low-volume distant metastatic disease was identified after
commencing NAC, which was continued and patients
underwent surgery as planned. Sixty-eight patients (74.2%)
received a combination of anthracycline-based chemother-
apy (5-fluorouracil, epirubicin and cyclophosphamide) andTable 1 Baseline tumour pathology and treatment characteristics
Total patients n = 87 n (%)
cT stage T1 T2 T3
1 (1.1%) 53 (60.9%) 18 (20.7%
cN stage N1 N2 N3
76 (86%) 7 (9%) 4 (5%)
Type of chemotherapy Anthracycline only Taxane only Combina
14 (16.1%) 5 (5.7%) 68 (78.2%
Trastuzumab Trastuzumab
34 (39.1%)
Type of surgery Breast conservation Mastecto
29 (33.3%) 58 (66.7%
Tumour grade G1 G2 G3
1 (1.1%) 23 (26.4%) 63 (72.4%
Tumour type Invasive ductal Invasive lobular Other
79 (90.8%) 4 (4.6%) 4 (4.6%)
Immunophenotype ER +/HER2 + ER +/HER2 ER −/HER
26 (29.9%) 30 (34.5%) 8 (9.2%)
Pathological response
of tumour
Complete response Near complete Partial re
15 (17.2%) 21 (24.1%) 41 (47.1%
Pathological assessment
of nodes
No residual metastasis ITC/ Mic only 1–2 nod
23 (26.4%) 10 (11.5%) 28 (32.3%taxane, and 34 patients (39.1%) had trastuzumab in com-
bination with chemotherapy (Table 1). Median time to
surgery was 6 weeks (4–12weeks) after the last cycle of
chemotherapy. In one patient surgery was delayed for 12
weeks resulting from investigation of a suspicious liver
lesion later confirmed as benign. Fifty-eight patients
(66.7%) underwent mastectomy and 29 (33.3%) had breast
conserving surgery. The median number of lymph nodes
retrieved at axillary clearance was 18 (7–34). The baseline
pathological features are detailed in Table 1.
Pathological assessment of breast tumour and axillary
nodal response
In the breast, pCR was reported in 15 patients (17.2%),
near CR in 21 patients (24.1%), PR in 41 patients
(47.1%), minimal response in 2 patients (2.3%) and no
response in 8 patients (9.2%) (Table 1).
Axillary node clearance pathological assessment re-
vealed no residual lymph node macrometastasis in 33
patients (37.9%), including 10 patients with residual ITC
or Mic identified. Twenty-eight patients (32.2%) had one
or two lymph nodes with macrometastasis, whereas 26
patients (29.9%) had more than 2 lymph nodes with re-
sidual macrometastasis (Tables 1 & 2). Twenty-eight pa-
tients had ITC or Mic disease, of whom 10 had only
ITC/Mic, 7 had also 1 or 2 nodes with macrometastasis,
and 11 had more than 2 nodes with macrometastasis. InT4
) 15 (17.2%)
tion
)
my
)
)
2 ER −/HER2 –
23 (26.4%)
sponse Minimal response No response
) 2 (2.3%) 8 (9.2%)
es with macrometasis More than 2 nodes with metastasis
) 26 (29.9%)
Table 2 Patient and tumour factors and association with level of axillary nodal burden on pathology
No residual macrometastatic
nodes n (%)
1–2 residual metastatic
nodes n (%)
More than 2 residual metastatic
nodes n (%)
p-value
Total 33 (37.9%) 28 (32.2%) 26 (29.9%)
Patient median age (years) 50.0 48.5 53.0 0.319
Trastuzumab given
yes 18 (53%) 8(23.5%) 8 (23.5%) 0.068
no 15 (28%) 20 (38%) 18 (34%)
Type of chemo
FEC 2 (14%) 7 (50%) 5 (36%)
Taxane 2 (40%) 2 (40%) 1 (20%) 0.325
both 29 (43%) 19 (28%) 20 (29%)
Tumour type
Ductal 30 (38%) 27 (34%) 22 (28%) 0.015
Lobular 0 (0%) 0 (0%) 4 (100%)
Other 3 (75%) 1 (25%) 0 (0%)
Tumour grade
1 0 (0%) 1 (100%) 0 (0%) 0.080
2 6 (26%) 12 (52%) 5 (22%)
3 27 (43%) 15 (24%) 21 (33%)
T staging
T1 1 (100%) 0 (0%) 0 (0%) 0.188
T2 21 (40%) 21 (40%) 11 (20%)
T3 7 (39%) 3 (17%) 8 (44%)
T4 4 (27%) 4 (27%) 7 (46%)
Immunophenotype
ER + ve/HER2 + ve 13 (50%) 8 (31%) 5 (19%)
ER + ve/HER2 -ve 6 (20%) 15 (50%) 9 (30%) 0.044
ER -ve/HER2 + ve 5 (63%) 0 (0%) 3 (37%)
ER -ve/HER2 –ve 9 (39%) 5 (22%) 9 (39%)
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nodal scarring in response to treatment in one or more
lymph nodes. Data were analysed including ITC and
Mic disease as a separate group, with no statistical dif-
ferences, and data shown in Table 2 include ITC and
Mic disease categorised as no residual macrometastatic
disease.
There was a statistically significant correlation between
breast tumour and axillary response as assessed by path-
ology: 86.7% (13 of 15) of those with tumour pCR, and
52.4% (11 of 21) of those who achieved near complete
response in the primary breast tumour had no residual
axillary disease respectively. In comparison, only 19.5%
(8 of 41) of those with partial response, and 10% (1 of
10) of those with no or minimal response in the breast
tumour proved to have no residual axillary disease re-
spectively (r = 0.495; p < 0.00001).Core biopsy factors and MRI assessment of breast and
axillary nodal response
Results of analysis of all treatment and tumour variables
and association with nodal response to treatment are
shown in Table 2. Patients with HER2 positive disease
(including both oestrogen receptor (ER) positive and ER
negative disease) had a significantly higher rate of nodal
complete response (p = 0.04). Although only small num-
bers of patients with lobular tumours were included, all
had high volume residual nodal disease (4 of 4 patients,
p = 0.015) (Table 2).
MRI response in the breast correlated significantly
with pathological response (r = 0.690; p < 0.000001).
Both interim and end-of-treatment MRI assessment of
response in the breast correlated with nodal burden at
ANC (p < 0.0001 for both) (Table 3) (Fig. 1). Only one of
10 patients (10%) with an MR CR at interim MRI had
Table 3 Presurgical imaging modalities and association with level of axillary nodal burden on pathology
No residual macrometastatic
nodes n (%)
1–2 residual metastatic
nodes n (%)
More than 2 residual metastatic
nodes n (%)
p-value
Total 33 (38%) 28 (32%) 26 (30%)
MRI breast tumour phenotype:
Mass 21 (41%) 20 (39%) 10 (20%)
Non-mass enhancement 4 (33%) 4 (33%) 4 (33%) 0.091
Both 8 (33%) 4 (17%) 12 (50%)
MRI breast interim chemo:
Complete response 10 (90%) 0 1 (10%)
Partial response 18 (40%) 18 (40%) 9 (20%) < 0.0001
Stable disease 3 (11%) 9 (33%) 15 (56%)
Progressive disease 0 (0%) 0 (0%) 0 (0%)
MRI breast post chemo:
Complete response 25 (64%) 9 (23%) 5 (13%) < 0.0001
Partial response 6 (15%) 16 (40%) 18 (45%)
Stable disease 2 (40%) 2 (40%) 1 (20%)
Progressive disease 0 (0%) 1 (100%) 0 (0%)
MRI axilla post chemo:
Normal 21 (46%) 13 (28%) 12 (26%) 0.087
Borderline 7 (39%) 7 (39%) 4 (22%)
Abnormal (partial response) 5 (31%) 3 (19%) 8 (50%)
Abnormal 0 (0%) 5 (71%) 2 (29%)
Fig. 1 Demonstrates the association of tumour response as predicted on interim-treatment breast MRI and the pathological findings in axillary
nodes r = 0.50; p < 0.0001. There were no patients with tumours showing progressive disease at interim MRI. Key: No residual macrometastasis in
axillary nodes =0; residual macrometastasis in 1 or 2 nodes =1–2; residual macrometastasis in more than 2 nodes = > 2
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with stable disease on interim MRI had residual macro-
scopic nodal disease (no patients had progressive disease
at interim MRI) (Table 3) (Fig. 1). The overall node-
negative conversion rate was 40% for the MRI PR group,
with a further 40% having 1–2 residual nodes, and 20%
with more than 2 positive nodes (Fig. 1). Core biopsy
tumour grade did not correlate with nodal response.Axillary imaging to predict response in axillary nodes
The axilla was assessed on MRI in 87 patients, and on
USS in only 48. There was no correlation with imaging
assessment of the axilla at interim or end-of-treatment
and nodal positivity rates, with high false-positive and
false-negative rates for those with data available for axil-
lary USS and for MRI (Table 3; Fig. 2) In the subgroup
of patients with MRI-reported abnormal nodes prior to
chemotherapy, and normal axillary MRI post-treatment
(n = 37), there were no abnormal nodes on surgery in 18
patients (48.6%), 1–2 nodes in 9 (24.3%), and more than
2 residual positive nodes in 10 (27.0%). There was there-
fore a false-negative rate of MRI axillary assessment of
27% for those with higher nodal burden of residual dis-
ease. Of those with MRI reported abnormal axillary
nodes after NAC, including nodes that remained abnor-
mal but showed partial response to treatment, 5 of 23
(21.7%) had no residual axillary nodal disease at surgery,Fig. 2 demonstrates the reported axillary response from MRI assessment p
clearance. There was no statistical correlationwhile 8 (34.8%) had 1–2 nodes positive, and 10 (43.5%)
had more than 2 positive nodes, thus a false-positive rate
of 21.7%.Discussion
We have shown in this series that 38% of patients will
have no residual macrometastatic axillary disease after
NAC, which is similar to that of NSABP B-18 and
American College of Surgeons Oncology Group trial
(ACOSOG Z1071) with 37 and 41% respectively [26],
and as such these patients could be spared ANC, with
consideration of axillary radiotherapy.
In the ACOSOG Z1071 trial the highest pCR rates in
both the breast and axilla were seen in HER2 positive
cancers at 45.4%, followed by triple negative cancers at
38.2%, whereas the pCR rate was only 11.4% in the
hormone-receptor positive category [14] The overall
pCR rate of 17.2% in our study was in accordance with
the expected rates taking in consideration that approxi-
mately two thirds of our study population were
hormone-receptor positive [14]. Our data show a better
response in nodal disease in HER2 positive tumours,
with no response in axillary nodes in the small number
of lobular cancers included.
The response in the breast at interim and end-of-
treatment MRI was found to correlate well with the
pathological response rates, as in previous studies [19–22].ost-treatment and the number of positive nodes from the axillary node
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breast and also, as shown in our data, to aid decision-
making regarding axillary surgery. Amongst all breast im-
aging modalities, contrast-enhanced (DCE) MRI has the
best accuracy and positive predictive value (PPV) for the
presence of residual breast disease. Furthermore, it has the
best NPV in predicting complete pathological response
(pCR) [19].
Our study was retrospective, utilising diagnostic MRI
images as performed in many breast centres, and as such
the metric chosen for analysis is one that can be
employed in any breast centre. We suggest that our re-
sults are more likely to be generalisable, since they are
independent of the postprocessing platform utilised. Dif-
fusion weighted imaging, although sensitive particularly
in identification of pCR, has the issue of a current lack
of standardisation across centres.
Both interim and end-of-treatment MRI were per-
formed in our patient group. It is plausible patients
whose tumours respond well at MRI after only 3–4 cy-
cles are very likely to have good nodal response, but
there was still a sizeable minority of patients with in-
terim MRI PR who went on to have MRI CR on comple-
tion of NAC (around 30%). Our data therefore suggest
that assessment of breast response on MRI should be
performed towards the end of NAC with sufficient time
to allow for surgical planning, but that a series of 3 MRIs
during treatment may not be necessary.
Stratification of tumour response on breast MRI has
been shown in our series to be indicative of axillary
nodal response. In accordance with the results of a sys-
tematic review, we did not find that MRI assessment of
the axillary nodes was helpful in this context, as there
were high false-positive and false-negative rates [23].
This is despite the fact that the breast tumour response
was evident at the time of reporting to the radiologist,
and one might expect some bias towards favourable as-
sessment of the axilla if breast tumour response is good,
but our data do not support this. Thus use of MRI to as-
sess the axilla does not aid decision making on axillary
clearance in our series. Importantly, when the axilla nor-
malised at MRI, over 54% of patients proved to have one
or more residual macrometastases at ANC.
Axillary USS (AUS) was not performed after treatment
in a number of patients in this series, as during the study
period it did not influence the outcomes for the patient
because of the local policy recommending ANC if nodal
disease had been proven prior to NAC. For those in
whom AUS results were available it did not appear to be
useful in addition to breast MRI response. AUS has pre-
viously been shown to surpass other modalities in axil-
lary lymph node assessment [19], although there has
been a wide variability in the reported sensitivity (27–
94%) and specificity (53–98%) [27, 28]. In order toascertain any additional benefit from AUS assessment of
axillary nodes after ANC, we are now routinely perform-
ing this at the end of NAC.
This study has some limitations, with relatively small
numbers of patients from a single institution. Nonethe-
less the results suggest that the findings are worthy of
consideration in a larger cohort of patients, as the im-
portance of breast MRI in prediction of axillary response
after NAC has not been well studied thus far. Our data
indicate that, taken together with tumour specific fac-
tors, breast MRI may be able to guide surgical decision
making for the axilla in the increasing number of breast
cancer patients treated with NAC.Conclusions
Contrast-enhanced MRI assessed response in the primary
breast tumour is very useful for predicting response in the
axilla, but axillary node assessment of response by DCE-
MRI is less accurate. An MRI complete response in the
breast was the only imaging factor we found to predict for
axillary response. If one considers that axillary radiotherapy
or perhaps no further local treatment may be an acceptable
alternative to ANC in patients with no macrometastatic
axillary disease after NAC, then a third of patients in this
series could have been spared ANC. From analysis of these
data, our local policy has been changed to incorporate MRI
breast response, immunophenotype tumour type including
HER2 positive and non-lobular type tumours, and AUS
where available to identify patients who now undergo SNB
rather than ANC, and we are auditing this change of
practice.
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